Navigation Links
Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
Date:12/20/2013

COPENHAGEN, Denmark, December 20, 2013 /PRNewswire/ --

Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announces the appointment of Annika Espander Jansson as a Non-Executive Director of the Board, with effect from 19 December 2013.

Annika has over twenty years' experience in the healthcare sector, both as a sell-side analyst and investor. She has a proven track record in strategic development of businesses and broad experience in managing operations in different segments of the financial markets.

Annika began her career as Equity Analyst and Sector Head of Healthcare at Aros Securities in Stockholm 1994-1996, followed by similar roles at Enskilda Securities, where she was Sector Head of Equity Research in Healthcare for five years, and Handelsbanken Capital Markets, where she gained experience of the financial services sector and became Group Head of Private Banking.  She joined Catella Healthcare, a private venture capital investor in healthcare companies, in 2004 as Managing Partner of a small team of professionals, during which time the IRR of the company's portfolio exceeded 35%.  Annika returned to Handelsbanken as Global Head of Private Banking in September 2010-June 2013 during which time the bank's ranking was upgraded to No. 1, according to the influential client survey - Prospera.

Annika is currently the founder and CEO of Asperia, a strategic and business advisory firm in the healthcare and financial services sectors. She is also a Board member of the public companies Stille AB and Probi AB, private portfolio companies Attana AB, Cellartis AB and Duocort AB, as well as the Swedish Financial Analyst Organisation. Annika holds a Ph.D. from the University of Gothenburg.

Welcoming the appointment, Göran Ando MD, Chairman of
'/>"/>

SOURCE Symphogen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
3. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
4. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
5. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
6. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
7. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
8. Pittcon Announces the 2014 Technical Program
9. AudioNotch Tinnitus Treatment Announces Holiday Sale
10. Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
11. DryLet, LLC Announces Investment from Ronald A. Chisholm Limited to Support Growth and Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study ... the study of the structure and functions of proteomes ... bioinformatics tools and technology. Genomics involves the mapping of ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... forecasts of its potential revenue from new rodenticide research ... investors and analysts on July 22, 2014, Neogen,s CEO ... regarding this research. "It was my intent ... the potential of a new type of rodenticide, but ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... the country's largest HMO announced it would discontinue a ... medical record system -- called the Clinical Information System ... Epic Systems , a relatively small private software developer ... ,So far, at least, Epic's been up to the ...
... it has also gotten on board with the real-time ... example of real-time technology. WisconsinGuide.com is helping to bring ... industry by allowing business owners the ability to quickly, ... , ,WisconsinGuide.com was featured on the WMTV NBC ...
... complaints of poor service from Wisconsin customers two years ago ... ,Paul La Schiazza, president of SBC's Wisconsin division said that ... was not a small local company, but a large corporation ... SBC Communications Inc. announced that SBC Ameritech of Wisconsin would ...
Cached Biology Technology:Kaiser On Schedule With Epic's Epic Project 2Kaiser On Schedule With Epic's Epic Project 3Wisconsin Tourism Aided by Internet Technology 2Wisconsin Tourism Aided by Internet Technology 3SBC is Here to Stay 2
(Date:7/25/2014)... use of a molecular testing panel developed at ... correct initial surgery for patients with thyroid nodules ... Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter., ... Center and other diagnostic testing agencies, improved the ... by 30 percent, according to the study published ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... DIEGO , July 24, 2014 /PRNewswire-iReach/ -- The ... data from cardiac devices, has cut emergency room wait ... UC San Diego (UCSD) Medical Center, according to a ... The UCSD Emergency Departments are using the suite to ... as pacemakers or defibrillators. "Using Geneva,s technology ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... CHAMPAIGN, Ill. We all know one, or think we ... his or her actual merits. Popular culture labels these folks ... suggests that some forms of narcissism are at least ... difficult transition to adulthood. The study appears ...
... relatively simple combination of naturally occurring sugars and amino acids ... according to a paper published in Nature Chemistry ... The study, " A Route to Enantiopure RNA Precursors ... to RNA could have formed on Earth before any life ...
... --- Farmers and policymakers should wait before converting Conservation Reserve ... Michigan State University study. The study, which appears ... National Academy of Sciences , focuses on CRP land, a ... than crops, and its role in the production of biofuels. ...
Cached Biology News:Narcissism may benefit the young, researchers report; but older adults? Not so much 2To avoid carbon debt, CRP beats fields of corn, soybeans 2